Long-term safety and effectiveness of leniolisib for immune problems
Part of Immune system & allergy clinical trials.
This study tests the long-term safety and effectiveness of the drug leniolisib for people with certain immune system disorders. It is for people who have already been in a previous study of this drug and may benefit from continuing treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in the earlier study LE 7201.
- Your doctor must think you will benefit from continuing leniolisib.
- You cannot have had a successful stem cell transplant from a donor.
- You cannot be taking certain other immune-suppressing medicines or have taken them recently.
- You cannot have certain serious health conditions, such as uncontrolled high blood pressure, heart failure, or severe liver or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a new blood test to find and monitor people with APDS, a rare immune disease, who may be helped by the drug leniolisib. It aims to improve how doctors screen and track treatment response.
This trial tests a targeted therapy called a PI3K inhibitor for people whose T-cell or NK-cell lymphoma has returned or not improved after other treatments. It aims to see if the drug can shrink or control the lymphoma.
This study looks at patients with a type of lymphoma (follicular lymphoma) who have already received a CAR T-cell therapy called liso-cel. Researchers want to track their health over time and see how well the treatment works and how safe it is in routine medical care.
This study is a long-term follow-up for people who already completed a 52-week study of the study drug litifilimab for active skin lupus. It will check the safety of continued treatment and see if it keeps helping symptoms.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests a combination of two drugs, linperlisib and chidamide, for people whose peripheral T-cell lymphoma has come back or not responded to at least one prior treatment. The goal is to see if this combination can shrink or control the lymphoma.
Hear when a new PIDs Linked to PI3K trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.